-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4608 Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Program: Oral and Poster Abstracts
Session: 641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Apoptosis, Lymphoid Leukemias, Research, CLL, Translational Research, Diseases, Lymphoid Malignancies, Biological Processes, Molecular biology
Monday, December 9, 2024, 6:00 PM-8:00 PM

Malte Knöll1*, Rashmi Priyadharshini Dheenadayalan, PhD2*, Deyan Y. Yosifov, PhD3*, Jialei Qi, MD4*, Christof Schneider, MD5*, Felix Seyfried, MD6*, Lueder Hinrich Meyer, MD6*, Paula Cramer, MD7*, Julia Von Tresckow, MD8*, Michael Hallek, MD9*, Barbara F. Eichhorst, MD9, Eugen Tausch, MD5*, Stephan Stilgenbauer, MD10 and Billy Jebaraj, PhD11*

1Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, AL, Germany
2University of Ulm, Ulm, Germany
3Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Baden-Württemberg, Germany
4University Hospital Ulm, Ulm, Germany
5Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany
6Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany
7Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany
8Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
9Department I of Internal Medicine, Faculty of Medicine and Cologne University Hospital, Cologne, Germany
10Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany
11Department of Internal Medicine III, Division of CLL, University of Ulm, Ulm, Baden Wurttemberg, Germany

Monoallelic deletion 13q (del(13q)) is the most common genomic aberration in chronic lymphocytic leukemia (CLL) and is associated with favorable prognosis when occurring as sole abnormality. In our analysis of genetic markers and outcome in CLL2-BAG, BCG, BIG, and BIO trials (CLL2-BXX, n= 242) of the German CLL study group, we identified among other genetic factors, the variant fraction of biallelic del(13q) (bidel(13q)) to be increased at disease relapse compared to baseline (median: 67% vs. 12.5%; n=7/42). This increase was significant with venetoclax based treatments (5/16; Yosifov et al., EHA 2023). Here, we further characterized associations of bidel(13q) with other genetic characteristics in the pretreatment setting and at relapse. Moreover, we functionally studied the role of bidel(13q) in response to venetoclax in ex vivo primary CLL samples and using in vitro models.

Firstly, we analyzed associations of bidel(13q) in n=3,327 treatment naive CLL. At baseline, bidel(13q) was significantly associated with lower incidence of the high and intermediate risk factors, unmutated IGHV (uIGHV), del(11q), trisomy 12 (all p<0.001) and del(17p) (p=0.015). On the contrary, when analyzing 55 relapse samples from the CLL2-BXX trials including BAAG and GIVe, bidel(13q) always co-occurred with del(17p). In 7 of 9 samples with increasing bidel(13q), the proportion of cells with del(17p) also increased, while in 2 of 9 samples bidel(13q) and del(17p) showed opposing trends. Next, we aimed to study the biological relationship between bidel(13q) and response to venetoclax.

MicroRNAs (miR) 15a and 16-1 present in the minimally deleted region of del(13q) in CLL were reported to regulate the anti-apoptotic proteins BCL2 and MCL1. To study the impact of biallelic loss of the miRs on venetoclax response, we screened CLL and mantle cell lymphoma (MCL) cell lines for a suitable model with sensitivity to venetoclax and presence of at least one wildtype 13q allele. MCL cell lines MAVER-1 (IC¬50 67nM) and MINO-1 (IC50 12nM) showed sensitivity to venetoclax in vitro. Fluorescence in situ hybridization identified MAVER-1 cells to harbor an intact 13q14 chromosomal locus, hence it was selected for further studies. The miRs 15a and 16-1 were knocked out in MAVER-1 cells by CRISPR-Cas9 and the knockout efficiency was verified at the DNA and RNA levels using PCR and qPCR, respectively.

Western blotting for anti and proapoptotic protein expression did not show substantial difference between the knockout cells and controls. Alternative mechanisms mediating a strong BCL2 upregulation could potentially mask the impact of miR knockout in MAVER-1 cells. However, cell cycle progression to S phase in the knockout cell lines was marginally increased (28% vs 20%), and the differences were not statistically significant. Analysis of venetoclax response and apoptotic priming using BH3 profiling identified no significant difference between the scrambled controls and miR knockouts. Since interaction with CD40L or TLR agonist CpG is known to alter expressions and dependencies on antiapoptotic proteins, we exposed the cells to CD40L and CpG prior to performing BH3 profiling. The miR knockout cells showed a decrease in apoptotic priming and an inferior response to venetoclax when exposed to CpG, however, the differences were not statistically significant (p=0.13).

We further characterized responses to venetoclax in the presence and absence of stimulation with CD40L, CpG, IL-2, IL-15, and IL-21 in samples with bidel(13q) and matched controls (n=6 each). All samples showed diminished responses to venetoclax upon stimulation with co-factors but samples with bidel(13q) and uIGHV showed a greater increase in venetoclax IC50 upon stimulation compared to uIGHV control samples (median: 26.1 vs. 6.3-fold). BH3 profiling identified decreased apoptotic priming in samples with bidel(13q) and uIGHV compared to corresponding uIGHV controls (median Δ priming to 0.1µM BIM: 16% vs 61%).

In summary, though bidel(13q) is strongly associated with good prognostic genetic factors and favorable outcome when occurring alone, the percentage of cells with bidel(13q) was increased at relapse after therapy with targeted agents, especially venetoclax in the CLL2-BXX trials and was associated with del(17p). Ex vivo analyses hint at diminished apoptotic priming when bidel(13q) occurs in the background of poor risk factors such as unmutated IGHV.

Disclosures: Yosifov: Roche: Other; Bayer: Other. Schneider: AstraZeneca: Honoraria; Abbvie: Honoraria; Janssen-Cilag: Honoraria. Hallek: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Eichhorst: Miltenyi: Consultancy; Lilly: Consultancy; AbbVie: Consultancy, Research Funding, Speakers Bureau; MSD: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; Kite: Consultancy, Speakers Bureau; Hoffmann-La Roche: Research Funding, Speakers Bureau. Tausch: Janssen: Consultancy, Other; AstraZeneca: Consultancy; BeiGene: Consultancy, Other; Roche: Consultancy, Research Funding; Abbvie: Consultancy, Other, Research Funding. Stilgenbauer: GSK: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Lilly: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Hoffmann-La Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Galapagos: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; BeiGene: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; Sunesis: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding, Speakers Bureau.

*signifies non-member of ASH